Na Cocer Peptides bin rayt am 
29 dez bifo
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Pεptid drog dεm εn tradishכnal sכm mכlikul dεm dεn tu de ple imכtant rol fכ divεlכpmεnt fכ dכg εn klinik aplikεshכn, bכt dεn difrεn pan dεn mεkanism fכ akshכn εn aplikεshכn kכntribyushכn.
Figure 1 Kכmpεreshכn כf saykli pεptida tεrapi to klasical sכm mכlikul dεm εn bayolojikal.
1. Mekanism fɔ Akshɔn
di mεkanism fכ akshכn fכ pεptida dכg dεm: Pεptida dכg dεm tipikכl de εksyεrt dεn ifekt bay we dεn de biεn spεsifi k rεsεpכta dεm na di bכdi. biכs fכ dεn strכkchכral similitu to εndojεnik bayoaktiv pεptida dεm, dεn kin spεshal rεkכgnεshכn εn biεn to kכrεspכndεnt rεsεpכta dεm, we de aktibכt כ inhεbit rεsεpכta-mεdiet signal path dεm fכ rεgεl sεlyul fysiolojikal fכnshכn dεm. insulin na tipik pεptida dכg we de biεn insulin rεsεpכta dεm na di sεl sεf, we de initiet wan siriכs signal transdyushכn prכsεs fכ protεkt glukכs כptek εn yutilizeshכn bay sεl dεm, we de mek di blכd glukכs lεvεl dכn.
sכm pεptida dεm kin miks di wok we nεchכral pεptida dεm de du. afta dεn tay to di rεsεpכta dεm na di sεl sεf, dεn de rεgεl di sεl prכsεs dεm lεk proliferashכn, difrεns, εn apoptosis, εn dεn de yuz dεm fכ trit difrεn sik dεm lεk kεnsar εn kכdivaskyul sik dεm. כda pεptida dεm kin akt lεk sabstεrayt כ inhibito dεm fכ di εnzym dεm, we de afekt εnzym aktiviti εn dat de rεgεl mεtabolik prכsεs dεm na di bכdi.
di mεkanism fכ akshכn fכ tradishכnal sכm mכlikul dεm: di mεkanism fכ akshכn fכ tradishכnal sכm mכlikul dכg dεm difrεn. bכku sכm sכm sכm mכlikul dεm de sho dεn ifekt bay we dεn de biεn di protin tכgεt dεm, we kin bi εnzym, rεsεpכta, ayכn chεnal, εtk nכnstεroyd anti-inflammatory drog dεm (NSAID) lεk aspirin de inhεbit di aktiviti fכ sayklooksijenεz (COX), we de ridyus di prostaglandin sεntesis, we de mek anti-inflammatory, analgesic, εn antipyretic ifekt dεm. di binding fכ sכm mכlikul dכg dεm to tכgεt dεm tipikכs de bays pan intamכlikul fכs dεm lεk haydrojεn bכnd, vεn dεr Waals fכs, εn ayכnik bכnd. sכm sכm sכm sכm mכlikul dεm kin put insay di DNA dכbl hεliks strכkchכ, we de intafεr di DNA rεplikshכn εn transkripshכn prכsεs, εn dεn kin yuz dεm fכ trit sik dεm lεk tכmכro. כda sכm sכm mכlikul dεm kin rεgεl di ayכn chεnal dεm na di sεl mεmbran dεm, we de afekt sεlyul εlektrofysiolojikal aktiviti dεm. fכ egzampl, antiaritmik dכg dεm de akt pan ayכn chεnal dεm na di kadyak mכsul sεl mεmbran dεm fכ rεgεl di kadyak ritm.
2. Aplikeshɔn dɛn
Aw fɔ yuz am fɔ trit sik - Pɛptid drɔgs: Pɛptid drɔgs de sho yunik advantej fɔ trit difrɛn sik dɛn. insay dayabεtis tritmεnt, apat frכm insulin, glukagon lεk pεptida-1 (GLP-1) analכg dεm na כda imכtant klas fכ pεptida dεm. Dɛn kin mek insulin kɔmɔt, dɛn kin mek di glukagon nɔ kɔmɔt, ɛn dɛn kin mek di gastric ɛmti, we kin mek di glukɔs we de na di blɔd go dɔŋ, wit bɛnifit dɛn lɛk fɔ mek di blɔd nɔ gɛt bɛtɛ blɔd ɛn fɔ kɔntrol di wet. insay kεnsar tritmεnt, sכm antikansa pεpti dεm kin biεn spεsifi k rεsεpכta dεm na di sεf fכ di tכmכro sεl dεm, we de mek di tכmכro sεl apoptosis כ inhibit di tכmכro angiojεnεsis, we de mek dεn rich di gol fכ sכpres di tכmכro gro εn mεtastas. insay di tritmεnt fכ di kכdivaskyul sik dεm, sכm pεptida dεm kin rεgεl di vaskulεr tכn εn inhεbit pletlet agregεshכn, we de ple imכtant rol fכ prεvεnshכn εn trit di kכdivaskyul sik dεm. Pεptid drog dεm gεt sכm limitεshכn dεm bak, lεk lכw כral bayoavaylabl, tipikli nid administreshכn via nכn-כral rod lεk injεkshכn, we to sכm mak de limited pasεnt kכvinεns fכ yuz mεdikeshכn.
Aplikeshɔn fɔ tritmɛnt fɔ sik - Tradishɔnal smɔl-mɔlikul drɔgs: Dɛn kin yuz tradishɔnal smɔl-mɔlikul drɔgs bɔku bɔku wan na klinik sɛtin, we kin kɔba difrɛn sik eria dɛn. Insay di wok we dɛn de du fɔ kɔntrol di infekshɔn, antibayɔtik ɛn ɔda smɔl smɔl mɛrɛsin dɛn kin stɔp ɔ kil baktri, vayrɔs, ɛn ɔda patɔjɛns, ɛn sev bɔku bɔku pipul dɛn layf. insay di tritmεnt fכ di kכdivaskyul sik dεm, statin dεm de inhεbit HMG-CoA rεduktaz fכ ridyus di kכlestכl sεntez, we de mek dεn prεvεnt εn trit di kכdivaskyul sik dεm. Insay di tritmɛnt fɔ saykayatrik ɛn nyurolɔjik dizayd, smɔl mɔlikul drɔgs lɛk antidipreshan ɛn antiɛpileptik drɔgs kin rigul di nyurotransmitta lɛvɛl ɔ di wok we dɛn de du, ɛn dis kin mek di sikman dɛn simptom dɛn bɛtɛ. di advantej dεm fכ sכm mכlikul dεm inklud rεlatεv hכy כral bayoavaylabl, wit mכst we dεn administret כral, we de rεsult in gud pasεnt kכmplians.
Sos dɛn we dɛn pul
[1] Ji X, Nielsen AL, Heinis C. Sayklik Pεptayd fכ Drug Divεlכpmεnt[J]. Angewandte Chemie Int ɛ rnash ɔ nal Ɛdyushɔn, 2023,63:e202308251.DOI:10.1002/anie.202308251.
[2] Rahman M. A., Akter S., Dɔrotea D, ɛn ɔda pipul dɛn. rεnoprotεktiv pכtεnshal dεm fכ sכm mכlikul nεchכral prodakt dεm we de tכk bכt mitochondrial disfכnkshכn[J]. Frɔntiers in Famakɔlɔji, 2022,13:925993.DOI:10.3389/fphar.2022.925993.
